Weight loss industry statistics that define the market right now
The weight loss industry is shaped by two numbers at once: the public health burden of obesity and the commercial response built around medications, programs, surgery, and digital subscriptions. The result is a market that is no longer centered on one channel or one company.
Here is a compact look at the biggest signals.
Table of contents
- Why the market is so large
- U.S. obesity by age and group
- State and regional patterns
- Global weight loss demand
- Company revenue signals
- Treatment and procedure benchmarks
- What the numbers say about market structure
Why the market is so large
The starting point is the prevalence of obesity. More than 2 in 5 U.S. adults have obesity, and obesity accounted for nearly $173 billion in medical expenditures in 2019 dollars (CDC Adult Obesity Facts). That combination of prevalence and spending pressure explains why the weight loss industry attracts so many business models at the same time.
The CDC said the prevalence of obesity among U.S. adults age 20 and over was 41.9% during 2017-March 2020 (CDC Adult Obesity Facts). The same source reported severe obesity at 9.2% during 2017-March 2020 (CDC Adult Obesity Facts). Those are not small niche figures. They imply a large addressable population for programs aimed at diet, behavior change, prescription drugs, surgery, and digital coaching.
The long-run trend also matters. Obesity prevalence increased from 30.5% in 1999-2000 to 41.9% in 2017-March 2020 (CDC Adult Obesity Facts). Severe obesity increased from 4.7% in 1999-2000 to 9.2% in 2017-March 2020 (CDC Adult Obesity Facts). In other words, the industry’s customer base expanded not just because the population grew, but because more people moved into higher-risk weight categories.
Fast facts
- Obesity was 41.9% among U.S. adults age 20 and over in 2017-March 2020 (CDC Adult Obesity Facts).
- Severe obesity was 9.2% among U.S. adults in the same period (CDC Adult Obesity Facts).
- Obesity-related medical expenditures were nearly $173 billion in 2019 dollars (CDC Adult Obesity Facts).
- Obesity prevalence rose from 30.5% in 1999-2000 to 41.9% in 2017-March 2020 (CDC Adult Obesity Facts).
U.S. obesity by age and group
Age matters because weight-loss products and services do not face the same adoption and risk profile across life stages. The CDC FastStats data for August 2021-August 2023 show 40.3% obesity among U.S. adults age 20 and older, and 72.4% overweight including obesity (CDC FastStats). That second number is especially important for market sizing because it captures a much wider potential audience than obesity alone.
Among younger groups, the same CDC FastStats source reported 22.9% obesity among adolescents ages 12-19, 22.1% among children ages 6-11, and 14.9% among children ages 2-5 (CDC FastStats). Those values show that the weight-management conversation begins early, even if the product mix differs sharply from adult treatment.
Age comparison table
| Group | Obesity prevalence | Source |
|---|---|---|
| Adults age 20+ | 40.3% | CDC FastStats |
| Adults age 20+ overweight including obesity | 72.4% | CDC FastStats |
| Adolescents ages 12-19 | 22.9% | CDC FastStats |
| Children ages 6-11 | 22.1% | CDC FastStats |
| Children ages 2-5 | 14.9% | CDC FastStats |
The age gradient in the CDC Adult Obesity Facts data also shows some clear pressure points. Obesity prevalence was 39.8% among U.S. adults aged 20-39 years, 44.3% among adults aged 40-59 years, and 41.5% among adults aged 60 years and older (CDC Adult Obesity Facts).
That middle-age peak matters because it overlaps with higher health-care utilization, stronger demand for prescription treatment, and greater concern about long-term comorbidities. It also means the weight loss industry is not just selling appearance-based outcomes. A large share of demand is tied to chronic disease risk management.
Group differences that shape demand
- Non-Hispanic Black adults had obesity prevalence of 49.9% in 2017-March 2020 (CDC Adult Obesity Facts).
- Hispanic adults had obesity prevalence of 45.6% in 2017-March 2020 (CDC Adult Obesity Facts).
- Non-Hispanic White adults had obesity prevalence of 41.4% in 2017-March 2020 (CDC Adult Obesity Facts).
- Non-Hispanic Asian adults had obesity prevalence of 16.1% in 2017-March 2020 (CDC Adult Obesity Facts).
These differences matter for outreach, access, and product design. A one-size-fits-all marketing model does not match the actual distribution of need.
State and regional patterns
The industry is also geographic. The CDC newsroom said that in 2023, 23 U.S. states had adult obesity prevalence at or above 35%, and at least one in five adults in every U.S. state had obesity (CDC newsroom, Sept. 12, 2024). That means the demand base is not concentrated in only a few places.
The CDC adult obesity maps for 2024 reported 35.9% obesity prevalence in the Midwest and 34.5% in the South, while the West was 30.2% and the Northeast was 30.3% (CDC Adult Obesity Prevalence Maps). Regional differences remain meaningful, but the gap is narrower than many people expect.
Regional snapshot
| Region | Adult obesity prevalence | Source |
|---|---|---|
| Midwest | 35.9% | CDC Adult Obesity Prevalence Maps |
| South | 34.5% | CDC Adult Obesity Prevalence Maps |
| West | 30.2% | CDC Adult Obesity Prevalence Maps |
| Northeast | 30.3% | CDC Adult Obesity Prevalence Maps |
At the state level, the CDC 2024 maps showed Mississippi and West Virginia as the only states at or above 40% adult obesity prevalence, with Guam also at or above 40% (CDC Adult Obesity Prevalence Maps). That is the kind of concentration that influences public health campaigns and commercial targeting.
The CDC self-reported obesity map for 2023 gives another way to see the spread. California had 27.7% adult obesity prevalence, Colorado had 24.9%, Alabama had 39.2%, Arkansas had 40.0%, Mississippi had 40.1%, and West Virginia had 41.2% (CDC self-reported obesity map). Even using self-reported measures, the difference between low-prevalence and high-prevalence states is large enough to affect local market strategy.
What the state data suggests
The state figures suggest three practical points.
- The industry has broad national demand, not just isolated regional demand.
- States in the South and parts of the central U.S. show persistently higher obesity prevalence, which tends to create stronger addressable demand.
- Low-prevalence states still have sizable populations with weight-management needs, so national brands cannot ignore them.
Global weight loss demand
The market is not only American. The World Health Organization said about 16% of adults aged 18 and older worldwide were obese in 2022 (WHO obesity fact sheet). It also said 2.5 billion adults were overweight in 2022 and 890 million adults were living with obesity in 2022 (WHO obesity fact sheet).
The trend line is clear. The WHO said worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled since 1990 (WHO obesity fact sheet). Those statements indicate a long-running global shift, not a temporary spike.
The WHO also reported that 35 million children under age 5 were overweight worldwide in 2024, more than 390 million children and adolescents ages 5-19 were overweight in 2022, and 160 million children and adolescents ages 5-19 were living with obesity in 2022 (WHO obesity fact sheet). That means the market touches households, pediatric care, and public health systems as well as adult consumer products.
Global market pressure points
- About 16% of adults worldwide were obese in 2022 (WHO obesity fact sheet).
- 2.5 billion adults were overweight in 2022 (WHO obesity fact sheet).
- 890 million adults were living with obesity in 2022 (WHO obesity fact sheet).
- 35 million children under age 5 were overweight worldwide in 2024 (WHO obesity fact sheet).
- 160 million children and adolescents ages 5-19 were living with obesity in 2022 (WHO obesity fact sheet).
The scale of the global population matters because it expands the market beyond one country’s reimbursement or consumer preference trends. Companies that can solve adherence, access, and affordability problems are competing in a very large pool.
Company revenue signals
The commercial side of the industry is easier to see in company results. Eli Lilly said Zepbound U.S. revenue was $4.93 billion in 2024 versus $175.8 million in 2023 (Eli Lilly 2024 Form 10-K). In the same company’s Q4 2024 sales release, Zepbound revenue was $4.9257 billion in 2024 and $175.8 million in 2023, while Mounjaro revenue was $11.5401 billion in 2024 and $5.1631 billion in 2023 (Eli Lilly Q4 2024 sales release).
Eli Lilly also said 2024 worldwide revenue was $45.0 billion, up 32% from the prior year, and that its six products each generated more than $3 billion in direct product and/or collaboration and other revenues in 2024, accounting for 75% of total revenues (Eli Lilly Jan. 14, 2025 guidance release; Eli Lilly 2024 Form 10-K). Those numbers show that obesity-related products are now part of a much broader revenue engine.
Novo Nordisk said Wegovy revenue grew 86% to DKK 58 billion in 2024, and total sales of obesity care products were DKK 65,146 million in 2024 versus DKK 41,632 million in 2023 (Novo Nordisk 2024 Annual Report). Novo Nordisk also said obesity care sales were majority Wegovy in 2024, and it invested more than DKK 129 billion in capital expenditure and acquisitions in 2024 to expand production (Novo Nordisk 2024 Annual Report). That is a direct sign that capacity, not just demand, is a strategic constraint.
WeightWatchers shows a different business model. It reported 2024 revenue of $785.921 million, subscription revenue of $776.993 million, digital subscription revenue of $512.853 million, workshops plus digital subscription revenue of $186.139 million, and clinical subscription revenue of $78.001 million (WW 2024 Form 10-K). It also reported about 0.1 million clinical subscribers at the end of fiscal 2024, and 3.3 million total end-of-period subscribers with 92 thousand end-of-period clinical subscribers in its 2024 results release (WW 2024 Form 10-K; WW FY2024 results release).
Hims & Hers adds yet another angle. It reported 2024 online revenue of $1.4379 billion, up 71% year over year, nearly $1.5 billion in total revenue, 2.2 million subscribers at year-end, and net income of $126 million (Hims & Hers 2024 Form 10-K; Hims & Hers FY2024 shareholder letter). The company said its weight loss offering helped drive 2024 online revenue growth (Hims & Hers 2024 Form 10-K).
Revenue comparison table
| Company | 2024 weight-loss or adjacent revenue signal | Source |
|---|---|---|
| Eli Lilly | Zepbound U.S. revenue $4.93 billion | Eli Lilly 2024 Form 10-K |
| Novo Nordisk | Wegovy revenue DKK 58 billion | Novo Nordisk 2024 Annual Report |
| WeightWatchers | Clinical subscription revenue $78.001 million | WW 2024 Form 10-K |
| Hims & Hers | Online revenue $1.4379 billion | Hims & Hers 2024 Form 10-K |
The revenue table is not a simple ranking of who is biggest. It is evidence that the weight loss industry now spans pharmaceuticals, subscriptions, digital care, and hybrid health platforms.
Treatment and procedure benchmarks
The treatment side of the market is also defined by clinical results and procedure volume. The FDA approved Zepbound for chronic weight management in adults on Nov. 8, 2023 (FDA press release). It approved Wegovy to reduce cardiovascular risk in adults with obesity or overweight and cardiovascular disease on Mar. 8, 2024 (FDA press release). Those approvals expanded the value proposition beyond weight loss alone.
The FDA said the Wegovy cardiovascular outcomes trial randomized over 17,600 participants (FDA press release). The same source also says Wegovy is approved for obesity or overweight and to reduce cardiovascular events in people at high risk (FDA MASH press release). That helps explain why GLP-1 drugs are discussed in both metabolic and cardiovascular contexts.
The FDA label for Zepbound showed 15 mg produced 20.9% mean body-weight change from baseline at 72 weeks in Study 1, 10 mg produced 19.5%, and 5 mg produced 15.0% (FDA label). The same label showed 90.9% of patients on 15 mg lost at least 5% of body weight, 83.5% lost at least 10%, and 70.6% lost at least 15% (FDA label). Those are unusually strong efficacy figures, and they help explain the speed of commercial adoption.
The FDA label for Wegovy showed 2.4 mg produced 14.9% mean body-weight change from baseline at week 68 in a labeled study, 1.7 mg produced 16.0%, and placebo produced 3.0% (FDA label). The same label showed 6.5% of placebo patients reached the relevant weight-loss threshold versus higher rates in the treatment arms (FDA label). That kind of difference supports the premium placed on drug efficacy in the current market.
Bariatric surgery remains part of the picture. ASMBS said more than 270,000 bariatric procedures were performed in the U.S. in 2023, and that 2023 volume was down 3.5% from the prior year (ASMBS 2025 fact sheet). ASMBS also said sleeve gastrectomy fell from 64% of all surgeries in 2020 to 58% in 2024 (ASMBS 2026 research release), and that U.S. metabolic and bariatric surgery procedures dropped below 200,000 in 2024 for the first time since 2020, with the decline from 2023 to 2024 more than 20% (ASMBS 2026 research release).
Procedure and drug signals side by side
- Drug demand is scaling quickly because efficacy and clinical risk-reduction claims are strong (FDA press release; FDA label).
- Surgical volume remains meaningful, but it is not growing as fast as the drug category in these data (ASMBS 2025 fact sheet; ASMBS 2026 research release).
- The market is moving toward a mixed-treatment model rather than a single dominant intervention.
What the numbers say about market structure
The weight loss industry is large because the underlying need is persistent, widespread, and measurable across age groups, states, and countries. The CDC and WHO figures show a population-scale problem. The company filings show that there is also a major commercial response.
What stands out most is not one single number. It is the interaction between them.
- High obesity prevalence creates demand.
- Rising severe obesity creates demand for higher-intensity treatment.
- Drug approvals and efficacy data expand what consumers and clinicians consider possible.
- Revenue growth at Eli Lilly, Novo Nordisk, WeightWatchers, and Hims & Hers shows where money is flowing.
- Bariatric surgery data show that older treatment models still matter, but they are sharing attention with newer pharmaceutical and digital options.
For anyone tracking the weight loss industry, the important question is no longer whether the market exists. The better question is how its mix changes as prescription drugs, subscription services, and surgical care compete for the same population of people trying to lose weight or reduce obesity-related risk.